Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq is approved in the US, EU and countries around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various forms of metastatic NSCLC, small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC), as well as certain types of metastatic urothelial cancer, PD-L1-positive metastatic triple-negative breast cancer and for the treatment of people with BRAF V600 mutation-positive advanced melanoma.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions.